Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;45(1):117-28.
doi: 10.1016/j.ecl.2015.09.008.

Statins and the Liver

Cynthia Herrick  1 , Samira Bahrainy  2 , Edward A Gill  3
Affiliations
Review

Statins and the Liver

Cynthia Herrick et al. Endocrinol Metab Clin North Am. 2016 Mar.

Abstract

Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are lacking. This review examines lipid physiology and cardiovascular risk in specific liver diseases and reviews the evidence for lipid lowering and the use of statins in chronic liver disease.

Keywords: Chronic liver disease; Dyslipidemia; Hepatic transaminases; Statins.

PubMed Disclaimer

Republished from

  • Statins and the liver.
    Herrick C, Bahrainy S, Gill EA. Herrick C, et al. Cardiol Clin. 2015 May;33(2):257-65. doi: 10.1016/j.ccl.2015.02.005. Cardiol Clin. 2015. PMID: 25939298 Review.

LinkOut - more resources